骨髓源性抑制细胞在癌症中的作用:机制见解和靶向治疗创新

IF 10.7 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
MedComm Pub Date : 2025-05-31 DOI:10.1002/mco2.70231
Tianying Hu, Jianxue Zhai, Zhanda Yang, Jiajia Peng, Chuxuan Wang, Xinyao Liu, Yawen Li, Jiaqi Yao, Fengxi Chen, Haixia Li, Taixue An, Zongcai Liu, Haifang Wang
{"title":"骨髓源性抑制细胞在癌症中的作用:机制见解和靶向治疗创新","authors":"Tianying Hu,&nbsp;Jianxue Zhai,&nbsp;Zhanda Yang,&nbsp;Jiajia Peng,&nbsp;Chuxuan Wang,&nbsp;Xinyao Liu,&nbsp;Yawen Li,&nbsp;Jiaqi Yao,&nbsp;Fengxi Chen,&nbsp;Haixia Li,&nbsp;Taixue An,&nbsp;Zongcai Liu,&nbsp;Haifang Wang","doi":"10.1002/mco2.70231","DOIUrl":null,"url":null,"abstract":"<p>Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that expand aberrantly in cancer and exhibit potent immunosuppressive properties. They contribute to tumor progression through both immunological and nonimmunological mechanisms. Immunologically, MDSCs suppress antitumor responses by inhibiting effector cells such as T cells and NK cells, facilitating immune evasion. Nonimmunologically, they promote tumor growth and metastasis through processes such as the epithelial‒mesenchymal transition, angiogenesis, and premetastatic niche formation. MDSC accumulation is closely linked to accelerated tumor progression, including resistance to both immunotherapies and conventional treatments, making these cells critical therapeutic targets. Clinical studies have demonstrated the potential of MDSC-targeted strategies to improve treatment efficacy. However, challenges remain in achieving specificity and effectiveness in MDSC-targeted therapies, emphasizing the need for a deeper understanding of their biology. This review summarizes the origin, classification, and biological characteristics of MDSCs, their dual roles in tumor progression, and their clinical significance. We also discuss recent advances in clinical and preclinical studies, including both traditional targeted therapies and emerging innovative strategies. By integrating current findings, we aim to provide a comprehensive perspective on the role of MDSCs in cancer and valuable insights for advancing cancer treatment and drug development.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":"6 6","pages":""},"PeriodicalIF":10.7000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mco2.70231","citationCount":"0","resultStr":"{\"title\":\"Myeloid-Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations\",\"authors\":\"Tianying Hu,&nbsp;Jianxue Zhai,&nbsp;Zhanda Yang,&nbsp;Jiajia Peng,&nbsp;Chuxuan Wang,&nbsp;Xinyao Liu,&nbsp;Yawen Li,&nbsp;Jiaqi Yao,&nbsp;Fengxi Chen,&nbsp;Haixia Li,&nbsp;Taixue An,&nbsp;Zongcai Liu,&nbsp;Haifang Wang\",\"doi\":\"10.1002/mco2.70231\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that expand aberrantly in cancer and exhibit potent immunosuppressive properties. They contribute to tumor progression through both immunological and nonimmunological mechanisms. Immunologically, MDSCs suppress antitumor responses by inhibiting effector cells such as T cells and NK cells, facilitating immune evasion. Nonimmunologically, they promote tumor growth and metastasis through processes such as the epithelial‒mesenchymal transition, angiogenesis, and premetastatic niche formation. MDSC accumulation is closely linked to accelerated tumor progression, including resistance to both immunotherapies and conventional treatments, making these cells critical therapeutic targets. Clinical studies have demonstrated the potential of MDSC-targeted strategies to improve treatment efficacy. However, challenges remain in achieving specificity and effectiveness in MDSC-targeted therapies, emphasizing the need for a deeper understanding of their biology. This review summarizes the origin, classification, and biological characteristics of MDSCs, their dual roles in tumor progression, and their clinical significance. We also discuss recent advances in clinical and preclinical studies, including both traditional targeted therapies and emerging innovative strategies. By integrating current findings, we aim to provide a comprehensive perspective on the role of MDSCs in cancer and valuable insights for advancing cancer treatment and drug development.</p>\",\"PeriodicalId\":94133,\"journal\":{\"name\":\"MedComm\",\"volume\":\"6 6\",\"pages\":\"\"},\"PeriodicalIF\":10.7000,\"publicationDate\":\"2025-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mco2.70231\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/mco2.70231\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedComm","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mco2.70231","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

髓源性抑制细胞(myeloid -derived suppressor cells, MDSCs)是一种异质的未成熟髓细胞群,它们在癌症中异常扩增,并表现出强大的免疫抑制特性。它们通过免疫和非免疫机制促进肿瘤的进展。在免疫学上,MDSCs通过抑制效应细胞如T细胞和NK细胞来抑制抗肿瘤反应,促进免疫逃逸。在非免疫方面,它们通过上皮-间质转化、血管生成和转移前生态位形成等过程促进肿瘤生长和转移。MDSC积累与肿瘤加速进展密切相关,包括对免疫疗法和常规治疗的耐药性,使这些细胞成为关键的治疗靶点。临床研究已经证明了mdsc靶向策略在提高治疗效果方面的潜力。然而,在实现mdsc靶向治疗的特异性和有效性方面仍然存在挑战,强调需要更深入地了解其生物学。本文综述了MDSCs的起源、分类、生物学特性、在肿瘤进展中的双重作用及其临床意义。我们还讨论了临床和临床前研究的最新进展,包括传统的靶向治疗和新兴的创新策略。通过整合目前的研究结果,我们的目标是提供一个关于MDSCs在癌症中的作用的全面视角,并为推进癌症治疗和药物开发提供有价值的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Myeloid-Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that expand aberrantly in cancer and exhibit potent immunosuppressive properties. They contribute to tumor progression through both immunological and nonimmunological mechanisms. Immunologically, MDSCs suppress antitumor responses by inhibiting effector cells such as T cells and NK cells, facilitating immune evasion. Nonimmunologically, they promote tumor growth and metastasis through processes such as the epithelial‒mesenchymal transition, angiogenesis, and premetastatic niche formation. MDSC accumulation is closely linked to accelerated tumor progression, including resistance to both immunotherapies and conventional treatments, making these cells critical therapeutic targets. Clinical studies have demonstrated the potential of MDSC-targeted strategies to improve treatment efficacy. However, challenges remain in achieving specificity and effectiveness in MDSC-targeted therapies, emphasizing the need for a deeper understanding of their biology. This review summarizes the origin, classification, and biological characteristics of MDSCs, their dual roles in tumor progression, and their clinical significance. We also discuss recent advances in clinical and preclinical studies, including both traditional targeted therapies and emerging innovative strategies. By integrating current findings, we aim to provide a comprehensive perspective on the role of MDSCs in cancer and valuable insights for advancing cancer treatment and drug development.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.70
自引率
0.00%
发文量
0
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信